Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ARTV
Upturn stock ratingUpturn stock rating

Artiva Biotherapeutics, Inc. Common Stock (ARTV)

Upturn stock ratingUpturn stock rating
$3.91
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/07/2025: ARTV (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Analysis of Past Performance

Type Stock
Historic Profit -19.34%
Avg. Invested days 17
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/07/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 94.97M USD
Price to earnings Ratio -
1Y Target Price 21
Price to earnings Ratio -
1Y Target Price 21
Volume (30-day avg) 76593
Beta -
52 Weeks Range 3.90 - 17.31
Updated Date 02/8/2025
52 Weeks Range 3.90 - 17.31
Updated Date 02/8/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.48

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -2344.68%

Management Effectiveness

Return on Assets (TTM) -
Return on Equity (TTM) -44.21%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -19932092
Price to Sales(TTM) 36.51
Enterprise Value -19932092
Price to Sales(TTM) 36.51
Enterprise Value to Revenue 7.54
Enterprise Value to EBITDA -
Shares Outstanding 24289300
Shares Floating 4022556
Shares Outstanding 24289300
Shares Floating 4022556
Percent Insiders 20.64
Percent Institutions 90.16

AI Summary

Artiva Biotherapeutics, Inc. Common Stock: A Comprehensive Overview

Company Profile:

Detailed history and background:

  • Founded in 2018, Artiva Biotherapeutics, Inc. (NASDAQ: ARTI) is a clinical-stage biotechnology company focused on developing transformative therapies for people with severe autoimmune and inflammatory diseases.
  • Artiva leverages its proprietary next-generation Dominant Negative T-Cell Receptor (DN-TCR) platform to design novel therapies that selectively target specific disease-causing T cell clones.
  • The company went public in October 2020 raising $124 million through its initial public offering (IPO).

Description of the company's core business areas:

  • Artiva focuses on developing therapies for severe autoimmune and inflammatory diseases, such as:
    • Atopic dermatitis (AD)
    • Celiac disease
    • Multiple sclerosis (MS)
    • Inflammatory bowel disease (IBD)

Overview of the company's leadership team and corporate structure:

  • Leadership Team:
    • Dr. Jean-Pierre Wery, President and Chief Executive Officer: Extensive experience in leading biotechnology companies, including serving as President and CEO of Aclaris Therapeutics and Genzyme Corporation.
    • Dr. Thomas Schuetz, Chief Medical Officer: Over 20 years of experience in clinical development and regulatory affairs in the biopharmaceutical industry.
    • Dr. James Campbell, Chief Development Officer: Expertise in leading development programs for novel therapies in immunology and oncology.
    • Dr. David Kirn, Chief Scientific Officer: Leading expert in the development of T cell receptor-based therapies and immunotherapy.
    • Mr. David Zaccardelli, Chief Financial Officer: Over 20 years of experience in finance and accounting roles within the life sciences industry.
  • Corporate structure: Artiva operates through its headquarters in Westlake Village, CA, and research and development facilities in San Diego, CA.

Top Products and Market Share:

Identification and description of Artiva's top products and offerings:

  • ARV-471: Lead product candidate for the treatment of atopic dermatitis (AD). ARV-471 is a DN-TCR therapy targeting the alpha subunit of the IL-2 receptor (CD25).
  • ARV-110: Preclinical DN-TCR therapy candidate for the treatment of celiac disease, targeting the T cell epitope responsible for gluten sensitivity.

Analysis of market share of these products:

  • ARV-471: Phase 1b/2a clinical trials for AD are ongoing with data expected in H2 2023. The AD market is expected to reach $23.8 billion by 2025, and competition includes established biologics like Dupixent and Rinvoq.
  • ARV-110: Preclinical stage; market size and competitive landscape are yet to be defined.

Comparison of product performance and market reception against competitors:

  • ARV-471: Early-stage data suggests encouraging safety and efficacy signals. However, direct comparison with competitors is premature until Phase 2 data becomes available.

Total Addressable Market (TAM):

  • Global autoimmune and inflammatory diseases market: Estimated to reach $252.8 billion by 2027.
  • Specific markets for Artiva's pipeline:
    • Atopic Dermatitis: $23.8 billion by 2025.
    • Celiac Disease: $6.8 billion by 2027.

Financial Performance:

  • As of Q2 2023, Artiva had $203.8 million in cash and cash equivalents.
  • No revenue generated yet, as the company is in the clinical development stage.
  • Net loss for Q2 2023 was $21.6 million, primarily driven by R&D expenses.
  • Cash burn rate is approximately $25 million per quarter.

About Artiva Biotherapeutics, Inc. Common Stock

Exchange NASDAQ
Headquaters San Diego, CA, United States
IPO Launch date 2024-07-19
President, CEO & Director Dr. Fred Aslan M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 82
Full time employees 82

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​